Kornimate/medical-research-clean huggingface dataset:
influence of bodily practices on the quality of life of women with endometriosis

Conditions: Endometriosis

Summary: this research focuses on understanding how physical activity can improve the quality of life for women with endometriosis by enhancing their self-perception, particularly regarding their physical abilities and appearance. the study is based on the idea that improving internal perceptions can lead to better overall well-being for these women. previous studies, suggest that physical self-perception plays a crucial role in shaping an individual's quality of life. there is also evidence supporting a reciprocal relationship between physical self-concept and participation in physical activity in this context, the research aims to explore how physical activity could positively influence the self-concept of women suffering from endometriosis, which in turn could enhance their quality of life. by focusing on improving both physical abilities and body image through regular exercise, this study seeks to offer insights into potential therapeutic approaches for managing the physical and psychological impacts of endometriosis.


Eligibility criteria:
inclusion criteria: * menstruating women aged 18 to 55; * proven diagnosis of endometriosis (pelvic ultrasound or mri) * having endometriosis-related pain of a level higher than 3 on the vas scale and/or chronic incapacitating symptoms related to endometriosis; * patient without treatment or with stable endometriosis treatment (pill and/or atg) who has not undergone treatment during the last 6 months; * patient affiliated to a health insurance scheme; * french-speaking patient; * patient having given free, informed and express oral consent. exclusion criteria: * any patient whose endometriosis treatment has been modified for less than 6 months; * having endometriosis-related pain greater than or equal to 8 on the vas scale; * cardiovascular risks related to physical training; * inability to perform proposed exercises; * patient under guardianship; * patient deprived of liberty;
treatment for sleep disturbance in orthopaedic trauma patients

Conditions: Sleep Disturbance; Trauma

Summary: the purpose of the study is to test the efficacy of sleep treatment in human patients following traumatic injury. specifically, the study will determine if treatment consisting of melatonin and education related to sleep habits are effective in treating sleep disturbance and improving sleep quality in orthopaedic trauma patients. we hope to learn if melatonin and sleep education effectively improve sleep following traumatic injury, and improve outcomes.


Eligibility criteria:
inclusion criteria: * new patients visiting the orthopaedic trauma clinic or undergoing orthopaedic surgery in stanford hospital following traumatic injury. accidental traumatic fracture injuries that are operative and non-operative. must be able to swallow tablets. exclusion criteria: * documented head trauma. cognitive impairments. minors. previously diagnosed sleep disorders. sleep apnea. enrolled in another study. women who are pregnant or may become pregnant or are nursing. hypertension. diabetes. endocrine, autoimmune, depressive, bleeding or seizure disorders.
the interaction between resting metabolic rate, physical activity and thyroid hormone in females

Conditions: Thyroid; Physical Activities; Resting Energy Expenditure

Summary: this study is focused on the interaction between resting metabolic rate (rmr), physical activity (pa), and thyroid hormones (th). th controls almost all the cell activities of the body so, it is known as one of the major regulatory hormones. this is the reason for individuals who suffer from thyroid disorders show abnormal metabolism. recently it was suggested that interindividual variations in thyroid hormone levels also influence daily physical activity.

in this study, investigators will recruit adult females with a bmi ≥18.5. after the screening process, eligible volunteers will undergo certain measurements including body composition, resting metabolism daily physical activity, thyroid hormone levels, and total energy expenditure. the investigators will access the changes in resting metabolism and daily physical activities with the differences in thyroid hormone levels.

Eligibility criteria:
inclusion criteria: * female age ≥18; * bmi≥18.5 exclusion criteria: * intended weight change exceeding 2kg within the past three months; * having any special medical diets or having eating disorders; * pregnant women or breastfeeding women; * people who have metal implants in their bodies; * patients with metabolic diseases, infectious diseases, and genetic disorders such as hypothyroidism, and hyperthyroidism; * patients with a personal or family history of medullary thyroid carcinoma (mtc), or patients with rare type 2 multiple endocrine tumor syndrome (men2); people with a fear of needles (trypanophobia), claustrophobia; people who are fear of blood (hemophobia) or pathological hypotension;
assessment of normal value of acoustic radiation force impulse (arfi) elastography in hiv patients

Conditions: HIV Infection

Summary: this is a prospective cohort single center study for assessment of normal value of acoustic radiation force impulse elastography and fibroscan in hiv patients without abnormal liver function and chronic liver disease.

hiv positive patients who have liver dysfunction have shown to be correlated with high mortality and morbidity. to date, arfi elastography has been known to correlate with the degree of liver fibrosis in chronic liver disease. however, arfi velocity has not yet been reported in hiv patients. the aim of this study was to identify the normal range of arfi velocity and liver stiffness value by recruiting hiv patients without abnormal liver function and chronic liver disease.

Eligibility criteria:
inclusion criteria: * age \> 20 years * hiv positive patients * the patients who is willing and able to provide written informed consent to participate in this study exclusion criteria: * co-infected with hiv and hbv or hcv * history of any other forms of liver disease * any gross abnormality on the imaging finding including mri and ct * any laboratory abnormalities regarding liver condition (platelet count \ 110 mg/dl, ast \> 40 iu/l, alt\> 40 iu/l, albumin \ 1.2 mg/dl, ggt\> 54 iu/l, alp \> 115 iu/l , ferritin \> 322 ng/ml)

Keywords: arfi imaging normal values hiv infection
disco application for the improvement of financial outcomes in patients with hematologic cancer

Conditions: Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Plasma Cell Myeloma

Summary: this phase ii trial studies how well the discussion of cost (disco) application (app) works in improving financial outcomes in patients with hematologic cancer. the disco app is an electronic, highly scalable and tailorable education and communication intervention that may help researchers learn more about improving how patients and oncologists discuss cancer treatment costs

primary objective: i. to assess the effectiveness of the disco app on prompting patient-oncologist treatment cost discussions during patient-physician interactions (as observed in video recordings), patient outcomes related to financial toxicity immediately after the patient-oncologist interaction, and at a 3-month follow up.

Eligibility criteria:
inclusion criteria: * oncologists: eligible if they treat patients with chronic lymphocytic leukemia (cll), chronic myelogenous leukemia (cml), or multiple myeloma (mm) cancers * patients: able to read and write in english * patients: have a confirmed diagnosis of cll, cml, or mm cancers * patients: are scheduled to see an oncologist at karmanos cancer institute (kci) detroit or kci farmington hills/weisberg for an initial or change in treatment discussion exclusion criteria: * none
a study of vx-659 combination therapy in cf subjects homozygous for f508del (f/f)

Conditions: Cystic Fibrosis

Summary: this study will evaluate the efficacy of vx-659 in triple combination (tc) with tezacaftor (tez) and ivacaftor (iva) in subjects with cystic fibrosis (cf) who are homozygous for the f508del mutation (f/f).


Eligibility criteria:
key inclusion criteria: * homozygous for the f508del mutation (f/f) * forced expiratory volume in 1 second (fev1) value ≥40% and ≤90% of predicted mean for age, sex, and height key exclusion criteria: * clinically significant cirrhosis with or without portal hypertension * lung infection with organisms associated with a more rapid decline in pulmonary status * solid organ or hematological transplantation other protocol defined inclusion/exclusion criteria may apply
organochlorine concentration in adipose tissue and pancreatic adenocarcinoma

Conditions: Carcinoma; Pancreatic Ductal

Summary: pancreatic adenocarcinoma represents more than 90% of pancreatic neoplasms. around 14000 new cases of pancreatic adenocarcinoma are being diagnosed each year in france and about 8.6% in grand est region. national incidence has doubled for men and tripled for women between 1982 and 2012. pancreatic adenocarcinoma is the deadliest digestive cancer, with only 7 to 8% all stages 5-year survival. it will become the second deadliest in europe, behind bronchopulmonary cancer. several risk factors have been identified such as diabetes, tobacco, chronic pancreatitis or obesity. however, a mismatch exists between incidence forecasts and actual risk factors knowledge. several hypothesis plead for an environnemental cause. plant protection products oncogenetic effects are known and have been proved to be responsible for tumors, including haematological malignancies. its role in pancreatic carcinogenesis is still poorly studied and show heterogeneous results. they do not allow to conclude for causality. organochlorines is a specific subset of plant protection product that store in lipids during lifetime. the aim is to study association between organochlorine concentration in adipose tissue with pancreatic adenocarcinoma.

unicentric prospective case control study comparing organochlorine levels including patients diagnosed with a pancreatic adenocarcinoma undergoing a surgery allowing to collect an adipose tissue sample (10g). controls are adults with no pancreatic cancer (excluded by a 6 months old computed tomography excluding the probability of a pancreatic neoplasm), paired with cases upon age and body mass index, with a scheduled surgical procedure allowing to collect an adipose tissue sample without extending procedure length.

Eligibility criteria:
inclusion criteria : cases : * patients diagnosed with a pancreatic adenocarcinoma, all stages allowed * undergoing a surgery allowing to take a 10 grams adipose tissue sample controls : * patients without a pancreatic neoplasm on a 6 months old ct scan before inclusion * undergoing a surgery allowing to take a 10 grams adipose tissue sample exclusion criteria : cases : * patients diagnosed with a pancreatic adenocarcinoma developed on ipmn or cystadenoma * patient with a known genetic predisposition increasing pancreatic adenocarcinoma risk * histopathology proof of a mixed neuroendocrine neoplasm * no surgery allowing to take a 10 grams adipose tissue sample controls : * patients with a pancreatic neoplasm on a 6 months old ct scan before inclusion * no surgery allowing to take a 10 grams adipose tissue sample

Keywords: plant production products risk factor adipose tissue organochlorine pesticides
seraseal for endoscopic hemostasis

Conditions: Gastrointestinal Hemorrhage

Summary: patients with active gastrointestinal bleeding can be included. 5ml of serasealtm/fastact (wortham laboratories, chattanooga, usa), a ce-certified medical product for in human intraoperative use as hemostatic agent, is topically applied via catheters to the bleeding site. in group a, seraseal is applied as initial method for hemostasis. in group b, seraseal is applied after an initial failure of the institutional standard method. homeostatic success is determined by 5 min without bleeding at gastrointestinal site. after application of seraseal.

following endoscopic confirmation of a bleeding, 2,5-5ml of liquid seraseal / fastact, certified for intraoperative use in humans (ce no 0653), is topically applied to the bleeding site. the delivery device consisted of a 5ml syringe containing seraseal plugged to standard delivery catheters, either ercp catheters or dye spraying catheters (boston scientific, usa) that are inserted via the working channel of the endoscope. once the bleeding is identified at endoscopy, the delivery catheter is inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip. seraseal is then delivered in short spray bursts or direct shots (for 1-2 seconds) until hemostasis is confirmed. a maximum of 5ml of seraseal is administered in each patient. homeostatic success is determined by 5 min without bleeding at gastrointestinal site. after application of seraseal. two groups are formed for analysis of this proof of concept study: in group a, seraseal is applied as initial method for hemostasis. if successful, the bleeding site is then observed for 5 minutes. if bleeding remains active or recurs, the institutional standard of care for hemostasis is applied. in group b, seraseal is applied as rescue therapy after an initial failure of the institutional standard method. if seraseal is successful, the bleeding site is then observed for 5 minutes. if the bleeding remains active or recurs after seraseal, alternative methods of hemostasis will be applied.

Eligibility criteria:
inclusion criteria: * active gastrointestinal hemorrhage exclusion criteria: * no sign of active bleeding at endoscopy

Keywords: gastrointestinal hemorrhage endoscopy hemostasis
down syndrome and continuous positive pressure therapy

Conditions: Down Syndrome; Obstructive Sleep Apnea Syndrome

Summary: the purpose of this study is to evaluate the efficacy and tolerability of continuous positive pressure for saos in down syndrome patients.


Eligibility criteria:
inclusion criteria: * down syndrome patients with an obstructive sleep apnea syndrome * more than 18 years old exclusion criteria: * predictable non-compliance of device * non-compensated cardiopathy * non-stable thyroxin treatment * non-stable diabetes

Keywords: down syndrome obstructive sleep apnea syndrome continuous positive pressure hypersomnia
azd9496 first time in patients ascending dose study

Conditions: ER+ HER2- Advanced Breast Cancer

Summary: this is a phase 1 open label multicentre study of azd9496 administered orally in patients with advanced er+ her2 negative breast cancer. the study design allows an escalation of dose with intensive safety monitoring to ensure the safety of patients. the study will determine the maximum tolerated dose. in addition, expansion cohort(s) at potential therapeutic dose(s) in patients with or without esr1 mutations will be enrolled to further determine the safety, tolerability, pharmacokinetics and biological activity of azd9496

a phase i, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of azd9496 in women with estrogen receptor positive her-2 negative advanced breast cancer

Eligibility criteria:
inclusion criteria: provision of signed and dated, written informed consent prior to any mandatory study specific procedures, sampling and analyses. aged at least 18 years. any menopausal status. pre- or peri-menopausal women must have commenced treatment with an lhrh agonist at least 4 weeks prior to starting study treatment and must be willing to continue to receive lhrh agonist therapy for the duration of the trial. histological or cytological confirmation of adenocarcinoma of the breast. er-positive according to local laboratory; her-2 negative. metastatic disease or locoregionally recurrent disease which is not amenable to treatment with curative intent. disease progression after at least 6 months of endocrine therapy for er+ breast cancer. radiological or objective evidence of progression on or after the last systemic therapy prior to starting study treatment. receipt of ≤2 lines of prior chemotherapy for advanced disease. females of child-bearing potential must agree to use adequate contraceptive measures, must not be breast feeding and must have a negative pregnancy test prior to start of dosing. eastern cooperative oncology group (ecog) performance status 0-1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks. exclusion criteria: any cytotoxic chemotherapy, investigational agents or other anti-cancer drugs for the treatment of advanced breast cancer from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment. any unresolved toxicities from prior therapy greater than common terminology criteria for adverse events (ctcae) grade 1 at the time of starting study treatment with the exception of alopecia. presence of life-threatening metastatic visceral disease, uncontrolled central nervous system metastatic disease or symptomatic pulmonary lymphangitic spread. any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection. unexplained symptomatic endometrial disorders. uncontrolled symptomatic thyroid dysfunction. inadequate bone marrow reserve or organ function

Keywords: phase 1 safety tolerability pharmacokinetics ascending doses estrogen receptor positive her2 negative advanced breast cancer
heart rate variability and cardiorespiratory complications during ophthalmic arterial chemotherapy for retinoblastoma

Conditions: Parasympathetic Cardiovascular Function Disorder

Summary: a patient undergoing ophthalmic arterial chemosurgery may experience a sudden, profound decrease in lung compliance when the microcatheter is in the ica or ophthalmic artery. however, underlying pathophysiology of the respiratory complication is unknown. in this study, the investigators are going to investigate the relation between underlying balance of parasympathetic and sympathetic tone and the respiratory complications by analyzing heart rate beat-to-beat variability.

a patient undergoing ophthalmic arterial chemosurgery may experience a sudden, profound decrease in lung compliance when the microcatheter is in the ica or ophthalmic artery. however, underlying pathophysiology of the respiratory complication is unknown. in this study, the investigators are going to investigate the relation between underlying balance of parasympathetic and sympathetic tone and the respiratory complications by analyzing heart rate beat-to-beat variability. also, the investigators are going to investigate whether baseline heart rate variability can predict respiratory complications during the procedures.

Eligibility criteria:
inclusion criteria: * patients undergoing ophthalmic arterial chemotherapy exclusion criteria: * none

Keywords: heart rate variability intraarterial chemotherapy ophthalmic arterial chemotherapy
the influence of lidocaine temperature on pain during subcutaneous administration

Conditions: Needlestick Injuries

Summary: this study will investigate the influence of lidocaine temperature on pain during injection of lidocaine. each participant will receive three injections subcutaneously on the abdomen with different temperatures. after each injection, participants will be asked to evaluate the pain on a visual analog scale (0-100 mm). it is anticipated that the pain decreases with increasing temperature. the aim of the study is to find a simple method for pain reduction that can be used in clinical practice.


Eligibility criteria:
inclusion criteria: * age 18-65 years exclusion criteria: * kidney, heart or liver disease * eczema or psoriasis on injection site * neuropathy * regular use of painkillers * hypersensitivity of lidocaine * pregnancy * diabetes

Keywords: injections temperature pain healthy volunteers lidocaine
three-year follow-up of participants after administration of boceprevir or narlaprevir for the treatment of chronic hepatitis c (p05063)

Conditions: Hepatitis C, Chronic; Hepacivirus

Summary: study p05063 is a 3-year long-term follow-up (ltfu) study in participants previously treated with boceprevir (boc) or narlaprevir (nar) in a phase 1, 2, or 3 clinical study. participants will be followed for up to 3.5 years after the end of their participation in the treatment protocol to document maintenance of the antiviral response (for sustained responders) and to characterize the long-term safety after use of this therapeutic regimen. ltfu procedures include collection of plasma samples for measuring hepatitis c virus ribonucleic acid (hcv-rna) by polymerase chain reaction (pcr) and hcv sequence analysis. no drug therapy will be administered as part of this study.

in part 1, participants who previously participated in one of nine boceprevir studies (p03523 \[nct00423670\], p03659 \[nct00160251\], p04487 \[no nct\], p05101 \[nct00708500\], p05216 \[nct00705432\], p05411 \[nct00959699\], p05514 \[nct00910624\], p05685 \[nct00845065\], and p06086 \[nct01023035\]) were followed for response. in part 2, participants who previously participated in one narlaprevir study (p05104 \[nct00797745\]) were followed for response.

Eligibility criteria:
inclusion criteria: * participant must be willing to give written informed consent and be able to adhere to the visit schedule. * participant must have received at least one dose of boceprevir or narlaprevir in a previous phase 1, 2, or 3 clinical study. exclusion criteria: * concurrent participation in any other clinical study for the treatment of chronic hepatitis c. * retreatment with any antiviral or immunomodulatory drug for chronic hepatitis c after completion of, or discontinuation from, the spri phase 1, 2, or 3 clinical study in which the participant previously participated. * any condition which in the opinion of the investigator would make the participant unsuitable for enrollment.
identification of potential biomarkers of peptide immunotherapy. part 1 - proteomics analysis

Conditions: Cat Allergy

Summary: cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. cat-pad is a novel synthetic, allergen derived peptide desensitizing vaccine currently being developed for the treatment of cat allergy. at present, the efficacy of immunotherapy (peptide or otherwise) can only be established at the conclusion of therapy. the aim of this study is to identify changes in potential biomarkers after peptide immunotherapy that may be subsequently developed as biomarkers that equate with clinical efficacy.


Eligibility criteria:
inclusion criteria: * male or female, aged 18-65 years * a minimum 1-year documented history of rhinoconjunctivitis on exposure to cats. * positive skin prick test to cat allergen with a wheal diameter at least 3mm larger than that produced by the negative control. * regular exposure to a cat in their normal living or working circumstances throughout the course of the study. * minimum qualifying rhinoconjunctivitis symptom scores exclusion criteria: * history of asthma * a history of anaphylaxis to cat allergen * a history of allergen immunotherapy in the previous 10 years, or in the previous 3 years for pre-seasonal immunotherapy treatments * a history of any significant disease or disorder (e.g. autoimmune, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, neoplastic/malignant, psychiatric, major physical impairment, severe atopic dermatitis)

Keywords: cat allergy rhinoconjunctivitis immunotherapy cat-pad